555 related articles for article (PubMed ID: 32552684)
1. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
[TBL] [Abstract][Full Text] [Related]
2. Pathological Role of Receptor for Advanced Glycation End Products in Calcified Aortic Valve Stenosis.
Saku K; Tahara N; Takaseya T; Otsuka H; Takagi K; Shojima T; Shintani Y; Zaima Y; Kikusaki S; Fukuda T; Oryoji A; Nishino Y; Matsui T; Kakuma T; Akiba J; Fukumoto Y; Yamagishi SI; Tanaka H
J Am Heart Assoc; 2020 Jul; 9(13):e015261. PubMed ID: 32552251
[TBL] [Abstract][Full Text] [Related]
3. Diabetes concomitant to aortic stenosis is associated with increased expression of NF-κB and more pronounced valve calcification.
Kopytek M; Mazur P; Ząbczyk M; Undas A; Natorska J
Diabetologia; 2021 Nov; 64(11):2562-2574. PubMed ID: 34494136
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus.
Farhan SS; Hussain SA
Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660
[TBL] [Abstract][Full Text] [Related]
6. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress.
Wei Q; Ren X; Jiang Y; Jin H; Liu N; Li J
BMC Cardiovasc Disord; 2013 Mar; 13():13. PubMed ID: 23497312
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis.
Ruggeri RM; Barbalace MC; Cristani MT; Alibrandi A; Giovinazzo S; Giuffrida G; Trimarchi F; Cannavò S; Campennì A
J Endocrinol Invest; 2020 Sep; 43(9):1337-1342. PubMed ID: 32232775
[TBL] [Abstract][Full Text] [Related]
10. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?
Prasad K
Mol Cell Biochem; 2019 Jan; 451(1-2):139-144. PubMed ID: 29961210
[TBL] [Abstract][Full Text] [Related]
11. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.
Kurt A; Andican G; Siva ZO; Andican A; Burcak G
J Physiol Biochem; 2016 Dec; 72(4):679-687. PubMed ID: 27448155
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
[TBL] [Abstract][Full Text] [Related]
13. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.
Yu Y; Hanssen KF; Kalyanaraman V; Chirindel A; Jenkins AJ; Nankervis AJ; Torjesen PA; Scholz H; Henriksen T; Lorentzen B; Garg SK; Menard MK; Hammad SM; Scardo JA; Stanley JR; Wu M; Basu A; Aston CE; Lyons TJ
BJOG; 2012 Nov; 119(12):1512-20. PubMed ID: 22900949
[TBL] [Abstract][Full Text] [Related]
14. Circulating Ligands of the Receptor for Advanced Glycation End Products and the Soluble Form of the Receptor Modulate Cardiovascular Cell Apoptosis in Diabetes.
Tsoporis JN; Hatziagelaki E; Gupta S; Izhar S; Salpeas V; Tsiavou A; Rigopoulos AG; Triantafyllis AS; Marshall JC; Parker TG; Rizos IK
Molecules; 2020 Nov; 25(22):. PubMed ID: 33182705
[TBL] [Abstract][Full Text] [Related]
15. Plasma glycation adducts and various RAGE isoforms are intricately associated with oxidative stress and inflammatory markers in type 2 diabetes patients with vascular complications.
Adeshara KA; Bangar N; Diwan AG; Tupe RS
Diabetes Metab Syndr; 2022 Mar; 16(3):102441. PubMed ID: 35247657
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients.
Jafari Nakhjavani MR; Jafarpour M; Ghorbanihaghjo A; Abedi Azar S; Malek Mahdavi A
Mod Rheumatol; 2019 Nov; 29(6):943-948. PubMed ID: 30474471
[No Abstract] [Full Text] [Related]
17. The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings.
Paradela-Dobarro B; Agra RM; Álvarez L; Varela-Román A; García-Acuña JM; González-Juanatey JR; Álvarez E; García-Seara FJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1050-1060. PubMed ID: 31371263
[TBL] [Abstract][Full Text] [Related]
18. Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer.
Zhou X; Lin N; Zhang M; Wang X; An Y; Su Q; Du P; Li B; Chen H
BMC Endocr Disord; 2020 Nov; 20(1):170. PubMed ID: 33187505
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Methylglyoxal-Induced AGEs/RAGE Expression Contributes to Dermal Protection by N-Acetyl-L-Cysteine.
Yang CT; Meng FH; Chen L; Li X; Cen LJ; Wen YH; Li CC; Zhang H
Cell Physiol Biochem; 2017; 41(2):742-754. PubMed ID: 28214842
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis.
Basta G; Corciu AI; Vianello A; Del Turco S; Foffa I; Navarra T; Chiappino D; Berti S; Mazzone A
Atherosclerosis; 2010 Jun; 210(2):614-8. PubMed ID: 20074734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
